Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7459-7469
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7459
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7459
Table 1 Sociodemographic characteristics of the study population n (%)
| Characteristic | TDF | LAM+ADV | Total | P value |
| (n = 22) | (n = 24) | (n = 46) | ||
| Age - average (range) | 53.14 ± 11.95 | 56.35 ± 11.86 | 54.82 ± 11.88 | 0.377 |
| Gender | ||||
| Male | 17 (77.3) | 22 (91.7) | 39 (84.4) | |
| Female | 5 (22.7) | 2 (8.3) | 7 (15.2) | |
| Weight - average (range) | 75.37 (46 - 105) | 78.72 (62 - 107) | 77.08 (46 - 107) | 0.663 |
| Height - average (range) | 1.68 (1.48 - 1.93) | 1.70 (1.56 - 1.80) | 1.69 (1.48 - 1.93) | 0.30 |
| BMI - average (range) | 26.59 (17.10 - 32.96) | 27.17 (21.45-34.54) | 26.89 (17.1-34.54) | 0.883 |
| < 18.50 - Underweight | 2 (9.10) | 1 (4.20) | 3 (6.50) | |
| 18.50 - 24.99 - Normal | 7 (31.80) | 8 (33.30) | 15 (32.60) | |
| 25.0 - 29.9 - Overweight | 9 (40.90) | 10 (41.70) | 19 (41.30) | |
| ≥ 30.0 - Obese | 4 (18.20) | 5 (20.8) | 9 (19.60) | |
| LAM resistance establishment | 0.725 | |||
| Clinical records | 18 (81.8) | 18 (75.0) | 36 (78.3) | |
| Resistance test | 4 (18.2) | 6 (25.0) | 10 (21.7) | |
| Cirrhosis, F4 state | 3 (13.6) | 1 (4.2) | 4 (8.7) | 0.336 |
| Diabetes mellitus and/ or hypertension | 2 (9.1) | 6 (25.0) | 8 (17.4) | 0.247 |
- Citation: Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, the TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469
- URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7459.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7459